


PHARMACEUTICAL 2019



ENANTA PHARMACEUTICALS INC Rank 9 of 371







PHARMACEUTICAL 2019



ENANTA PHARMACEUTICALS INC Rank 9 of 371



The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 481% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 333%, being 665% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	380,389
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,025
Liabilities, Non-Current	2,895
Other Assets	25,464
Other Compr. Net Income	-286
Other Expenses	21,165
Other Liabilities	1,628
Other Net Income	4,793
Property and Equipment	8,374
Research and Development	94,856
Revenues	206,625
Selling, General and Administrative Expense	23,441

Output Variable	Value in 1000 USD
Assets	414,227
Liabilities	20,548
Expenses	139,462
Stockholders Equity	393,679
Net Income	71,956
Comprehensive Net Income	71,813
Economic Capital Ratio	333%

